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Microchimerism (MC), defi ned by the persistence of <1% circulating donor cells resulting from cell migration from the graft, may play a role in the induction of unresponsiveness to allogeneic tissues, or may be merely the consequence of the graft's acceptance following immunosuppression. To monitor and compare MC in patients early and late after liver transplantation we set up a highly sensitive nested PCR protocol allowing the detection of HLA-DRB1*01, *04, *11, or A*02 donor alleles. MC was measured in multiple samples (from 3 DNA extractions, PCRs/ time point, 200 ng DNA/PCR) obtained from 17 patients. Results were expressed as percent positive PCRs/time point (detection level: 1 donor cell/105 patient's cells). In 8 patients MC was measured early (0-3 months) and late (4-12 months). All patients had detectable early MC, ranging from 10 to 100% pos. PCRs.In one patient MC remained high (from 100% to 80%), while in the other patients MC decreasd to <40% after 4-12 months. In the 9 patients where MC was measured only later then 1 year, low levels of MC (0-18% pos. PCRs) were detected. In 2 patient samples cell fractionation was performed, and positive MC could be detected in the CD3+ cells, excluding the presence of circulating donor hepatocytes. Mild rejection occurred in 3/4 patients with low (20% pos. PCRs) early MC, while 3/3 patients with high (50-100%) early MC had no rejection. These data support the hypothesis that early MC is a key event for the induction of tolerance in the rat (Ko et al., Nat. Med. 1999; 5: 1292) . The high dose of passenger leucocytes observed in liver grafts might be one reason of the permissiveness with respect to HLA compatibility.
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LOSS OF HETEROZYGOSITY OF THE B2M GENE DETECTED WITH MICROSATELLITE MARKERS DOES NOT REFLECT B2M GENE COPY NUMBER IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
Geert JPA Koene, Yvonne HA Arts-Hilkes, Kevin JW van der Ven, Piet J Slootweg, Roel A de Weger and Marcel GJ Tilanus. Pathology, UMC Utrecht, Utrecht, the Netherlands.
HLA has a pivotal function in the immune system. Presentation of endogenously derived peptides by HLA class I and B2m offers the immune system a mechanism to monitor intracellular events. Infection and tumorgenesis can alter the peptide pool presented on the cell surface. This may lead to cytotoxic T-cell responses by which non-healthy cells can be eradicated. Reduced HLA expression affects the ability to detect non-healthy cells (e.g. cancer cells) and therefore provides an escape mechanism for tumor cells. To predict altered HLA expression in tumors, loss of heterozygosity (LOH) of HLA and the B2m gene is widely studied using microsatellite markers. We studied LOH of the B2m gene in 53 head and neck squamous cell carcinoma (HNSCC) using 6 microsatellite markers fl anking the gene and immunohistochemical staining of B2m. Since LOH can not distinguish loss from amplifi cation, we also determined the copy number of chromosome 15, where B2m is located, in 11 HNSCC using centromere 15 fl uorescence in situ hybridization (FISH). Chromosome 1 FISH was used as control. Summarized, chromosome 15, but also chromosome 1 was affected in all 11 HNSCC. Four HNSCC with LOH and positive B2m expression showed amplifi cation of chromosome 15 instead of the predicted loss. It can be concluded that B2m microsatellite LOH does not refl ect the B2m gene copy number in these HNSCC. LOH does not merely detect loss but also gain of a genomic region. Moreover, the majority of the tumors showed a variety of aneuploidy for chromosome 15 as well as chromosome 1 within the tumor. This demonstrates that these HNSCC are heterogeneous.
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HUMAN LEUKOCYTE ANTIGEN LOSS DETERMINED BY MICROSATELLITE MARKERS IS NOT CONCLUSIVE AS INDICATED BY FISH
Geert JPA Koene, Yvonne HA Arts-Hilkes, Anette van Dijk, Kevin JW van der Ven, Piet J Slootweg, Roel A de Weger and Marcel GJ Tilanus. Pathology, UMC Utrecht, Utrecht, the Netherlands.
The Human Leukocyte Antigens (HLA) are a key component in human tumour immunology. Presentation of tumour antigens (TA) by HLA class I allows specifi c targeting of tumour cells. Loss of HLA expression does not only increase tumour development and progression, but also hampers the applicability of immune therapy. Genomic loss of HLA is frequently observed in tumours, in particular loss of heterozygosity (LOH). LOH is often studied using microsatellite (STR) markers. However, STR markers can not distinguish genomic loss from gain. Therefore, we studied LOH and HLA protein expression in 53 head and neck squamous cell carcinoma (HNSCC) and selected 9 tumours for HLA fl uorescence in situ hybridisation (FISH) to evaluate the LOH data.HLA immunohistochemical staining was performed with W6/32 on 4 um paraffi n sections.STR markers D6265, C125 and TAP1 were used to determine LOH of the HLA region. FISH was performed on 6 um paraffi n sections using a chromosome 6 centromeric probe and propidium iodide to stain the nuclei. FISH signals were analysed by two independent persons. For fi ve out of the nine tumours selected for FISH, the LOH data are not in concordance with the FISH data: in two HNSCC with loss of one chromosome 6, LOH was not detected using the STR markers; in a tumour with LOH and one without LOH, gain of chromosome 6 was detected by FISH rather than loss or normal chromosome 6 presence; lastly one tumour was clearly heterogeneous and showed loss as well as gain of chromosome 6 although only LOH was detected with the STR markers. STR markers can not distinguish loss from gain and give no representative information on the copy number of a genomic region. Additional techniques like immunohistochemical staining with allele specifi c antisera and FISH are necessary to determine specifi c HLA loss. The HLA-B27 confers susceptibility to ankylosing spondylitis (AS). We demonstrated previously that the polymorphism of B27 alleles infl uence the susceptibility to AS. However the mechanism linking this association with AS remain unknown. Other properties unrelated with its natural role of antigen presenting function may be important in disease pathogenesis. We determine the impact of Asn97Asp change on the folding and expression of B*2704 transfected in 721.221 cell line. We examined by fl ow cytometry the surface expression of B*2704 and the B*2704 Asn97Asp. The mutation at positions 97 abolish the expression of non-conformational (HC-10) and conformational (ME-1) forms. It might be questioned whether the absence of surface expression of Asp97 mutant correlates with the intracellular forms. The expression of conformational form was found to be absent in B*2704 Ans97Asp as seen for immunoprecipitation experiments with the conformation-sensitive ME-1 antibody. Therefore, immunoblotting cell lysates with HC-10 revealed the presence unfolded HC and HC-dimer forms. In addition, we determine the impact of Asn97Asp mutant on the maduration of B2704 in 221 cell. Samples were treated with endo-H and analysed by Western blot by using HC-10 antibody to assess exit from the ER. This approach revealed that B*2704 wild type molecules were exported from the ER to Golgi. In contrast, the mutant N97D was not exported to Golgi suggesting that they were retained and accumulated as unfolded molecules. To determine if the Asn97Asp mutation had an effect on interactions with chaperons, we tested for mutant association with TAP, CNX and CLR. As expected, the wild type B*2704 molecule associates with TAP, CNX and CLR. In contrast HC-10 form of mutant N97D remain capable to bind TAP but interact weakly, but were associated with CRT and CLX as similar levels that wild type. Several hypothesis have been formed to account for the strong association between HLA-B27 and AS. The arthritogenic theory proposes that AS is a consequence of the antigen presentation function of HLA-B27. Alternatively, it has been suggested that AS may arise because of aberrant folding of HLA-B27 molecules within the environment of the endoplasmic reticulum Accumulation of unfolded proteins in the ER may cause unfolded protein responses (UPR). Future work must aim to clarify the functional connection between the UPR pathway in response to unfolding of B27 and stress in the ER. This mutant would be useful as a model of misfolding of HLA-B27. MICA molecules interact with the NKG2D activating receptor on human NK and CD8 T cells. Given the knwon expression of MICA in the intestinal epithelium, we investigated the participation of the MICA-NKG2D interaction in the destruction of intestinal villous epithelium by intraepithelial T lymphocytes (IEL) in celiac disease, and its malignant complication, refractory sprue. We show here that MICA is strongly expressed at the surface of small intestine epithelial cells in patients with active disease. Moreover, MICA is induced by gliadin or gliadinderived peptides, upon in vitro challenge in organ cultures. This triggers direct activation and/or costimulation of IEL through engagement of NKG2D, leading to an innate-like cytotoxicity towards epithelial targets and enhanced TCR-dependent CD8 T cell mediated a daptive response. Villous atrophy in celiac disease might thus be ascribed to an IEL-mediated damage to enterocytes through the NKG2D-MICA interaction following gliadin-induced expression of MICA at the surface of gut epithelium. Therefore, MICA may represent the missing link in the pathogenesis of celiac disease.
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THE PROGNOSTIC RELEVANCE OF SOLUBLE HLA-G LEVELS FOR THE SURVIVAL OF BRAIN TUMOR PATIENTS
Vera Rebmann*, Jens Regel**, Beate Schoch**, Dietmar Stolke**, and Hans Grosse-Wilde* *Institute of Immunology and **Department of Neurosurgery, University Hospital of Essen, 45122 Essen, Germany
The immune system of patients suffering from human brain tumors especially from glioblastoma multiforme (GBM) is characterized as broadly suppressed immune system. High levels of Th2 cytokines such as IL-10 are discussed to be partly responsible for this immune impairment. As soluble HLA molecules are capable to inhibit T and NK cell functions we analysed the plasma concentrations soluble HLA class I (sHLA-I), HLA-G (sHLA-G), HLA-DR (sHLA-DR) and IL-10 molecules in 58 brain tumor patients (40 with GBM, 7 with astrocytoma, 7 with brain metastasis, and 4 with other brain tumors). Compared to age matched healthy controls the IL-10 level of brain tumor patients was signifi cantly increased (11.4 ± 7.2 SEM pg/ml vs. 19.1 ± 4.3 SEM pg/ml; p<0.0001), whereas the sHLA-I levels are slightly reduced (1.2 ± 0.1 SEM µg/ml vs. 0.9 ± 0.1 SEM µg/ml; p=0.012). Although the sHLA-G and sHLA-DR levels of the patients (24 ± 2 SEM ng/ml and 1.1 ± 0.2 SEM µg/ml, resp.) were in the range of controls, nonparametric discriminant analysis combined with Mann Whitney test showed that sHLA-G levels < 13.5 ng/ml (N=13) are associated with a better and sHLA-G levels > 13.5 (N=45) with a worse overall survival (mean survival: 20.6 ± 2.3 vs. 10.7 ± 1.3 SEM months; p=0.0005). This fi nding was further supported by Kaplan-Meier analysis (p=0.0036). For HLA-I, sHLA-DR, and IL-10 levels no infl uence on the overall survival could be observed. In conclusion, our results showed that especially sHLA-G levels are of prognostic value for the overall survival of brain tumor patients. This suggests, that systemically high levels of sHLA-G are more relevant than other sHLA molecules or IL-10 for a suppression of the immune system. A negative cytotoxic T lymphocyte precursor (CTLp) assay in the graft versus host direction between an HLA mismatched stem cell donor and recipient predicts good graft outcome. So far it has been impossible to predict, which HLA class I mismatches will lead to a negative CTLp test. We analysed CTLp assays, performed on 80 single HLA class I mismatched stem cell donor/patient couples (all matched for HLA-DRB1 and -DQB1), to assess whether the CTLp assay outcome is infl uenced either by the total number of amino acid differences or amino acid differences at specifi c positions on the HLA molecule. All donor / patient couples were typed for HLA-A*, -B*, -Cw*, -DRB1* and -DQB1* at the allele level. According to our results there is neither a relation between the total number of amino-acid differences and cytotoxicT-cell alloreactivity, nor is variation on a specifi c positions on the HLA class I molecule predictive for T-cell alloreactivity. Contrary to our expectations we observed that mismatched HLA-Cw antigens, with a high number of substitutions on the α helices (fi ve or more) lead to undetectable CTLp frequencies (p= 0.0285). Most of these couples had also at least fi ve amino-acid differences on the β sheet. These results were further substantiated with 8 new couples. A possible explanation for this unexpected fi nding is that T-cells able to react with these HLA-C mismatches have been eliminated by selection mechanisms in the thymus; which leads to a pool of T-cells that preferentially associate with self-HLA class I molecules. We investigated prostate-specifi c membrane antigen (PSMA) peptides activation and i.c.IFNg production in CD4 + and CD8 + cells of patients with prostate cancers. Five vaccinated and 4 non-vaccinated HLA-A2 positive patients were tested. The immunizations were done over a 2.5-year period alternating between PSMA/CD86 and recombinant adenoviral Ad5PSMA vaccines. Blood samples were stimulated with the following peptides: p1-MMNDQLMFL; p2-ALFDIESKV; p3-LMYSLVHNL(Sigma Genosys) and PHA as a positive control. De novo expression of CD69 and i.c.IFNg were evaluated by FASTImmune Intracellular CD4 and CD8 Cytokine Detection kits(BD) and fl ow cytometry. Serum antibodies were tested by ELISAs with the same peptides as coating antigens. All patients were in good clinical condition with normal lymphocyte counts, as well CD4+ and CD8+ subsets. All of them reacted to PHA similarly to healthy persons, namely they had preserved cellular immune competence. There was no difference in these reactions between DNA-vaccine treated and non-treated patients. We found p1-specifi c CD4+CD69+ cells in 3 patients and IFNg+CD4+ cells in 4 patients treated with vaccine and in no one of non-treated. Two of 5 treated patients showed increased IFNg+CD8+ induction to p1 and p2 peptides. Antibodies against all tested peptides were found only in the sera of the vaccinated patients. Our results show that, fi ve years after immunotherapy with a gene-based vaccine targeting PSMA, a recall p1-specifi c CD4+ and p1 and p2-specifi c CD8+ cellular immune responses still exists, as well as anti-PSMA-peptide antibodies in the vaccinated patients. In studies with human dendritic cells we showed that when immature DC were triggered through CD40 or LPS in the presence of the corticosteroid dexamethason, these cells were unable to acquire high levels of costimulatory and MHC class II molecules. Importantly Dex modifi ed the CD40-or LPS activated DC cytokine secretion profi le by suppressing IL-12 production and by stimulating the secretion of high levels of IL-10. These alternatively matured DC displayed a decreased allostimulatory potential concerning IFNg producing cells whereas IL-10 producing cells were induced. Furthermore, these IL-10 producing cells were able to downregulate the alloimmune response of both CD4+ cells and CD8+ positive cells. The immunomodulatory effect of alternative matured DC was further tested in a mouse model. Mouse dendritic cells (C57BL/6; H-2b) were pretreated with dexamethason and cultured in the presence and absence of LPS. In line with their phenotype,including decreased IL-12 production, in vitro co-culture of alternatively matured DC of C57BL/6 origin with completely allogeneic T cells of BALB/c origin lead to a signifi cant decrease in the alloreactive T cell response. A single injection of 1 x 106 alternatively matured C57BL/6 DC into BALB/c mice induced an alloimmune response of the T cells as measured by proliferation and IFN-g production in vitro, which was lower than the response observed after injection of mature DC. Furthermore, the number of IL-10 producing cells was increased. Interestingly, injection with alternatively matured DC, followed by transplantation of fully mismatched skin grafts (C57BL/6), led to a signifi cantly prolonged survival compared to that of either mature DC pretreated mice or untreated mice. The present data suggest that "tolerogenic" DC may become an attractive tool for the induction of transplantation tolerance in the clinical setting. The cynomolgous macaque is one of the non-human primates mostly used as a model for immune related diseases. Therefore, a thoroughly known MHC of this species is needed. In contrast to the rhesus macaque, little is known about the MHC of the cynomolgous macaque (MhcMafa). Since specifi c MHC antisera are lacking, serological typing of the monkey is hampered. Therefore, molecular characterization of the polymorphic Mafa class II genes has been performed by direct sequencing of exon 2 of -DQA1 and -DQB1, as well as pre-screening of -DRB genes by denaturing gradient gel electrophoresis (DGGE). In one cynomolgous macaque family of 16 members constituting 4 generations, 11 -DQB1 and 9 -DQA1 alleles have been detected. In contrast to humans, Mafa-DQA1 seems to be as variable as -DQB1, and both genes are more polymorphic than their equivalents in the rhesus macaque. Like the Mafa-DQB1 alleles, the -DQA1 alleles belong to lineages already described in the rhesus macaque and/or humans. The exon 2 sequences of some -DQA1 alleles are identical to those of the rhesus macaque, thus confi rming a trans-species mode of evolution. In DGGE, Mafa-DRB alleles show highly variable patterns, with 2 up to at least 5 loci per haplotypes. As in rhesus macaques, DQA1/DQB1 of the cynomolgous monkey seem mostly to segregate as unique combinations which are coupled to one or more -DRB region confi gurations. This study allows to conclude that cynomolgous macaques possess an exceptionally high number of different DQ/DRB haplotypes. Therefore, cynomolgous macaques have to be at least as thoroughly typed for their variable Mhc genes as rhesus macaques before immunological studies can be performed. In the human population, 5 major HLA-DRB haplotypes have been identifi ed, whereas the situation in rhesus macaques (Macaca mulatta) is radically different. At least 30 Mamu-DRB region confi gurations, displaying polymorphism with regard to number and combination of DRB loci present per haplotype, have been characterised. Until now, Mamu-DRB region genes have been studied mainly by genomic sequencing of polymorphic exon 2 segments. Relatively little is known, however, about the expression status of these genes. To understand which exon 2 segments may represent functional genes, full-length cDNA analyses of -DRA and -DRB were initiated. In contrast to humans, Mamu-DRA was found to be polymorphic, and 11 cDRA alleles were identifi ed in Indian rhesus macaques only, representing four distinct gene products. Amino acid replacements are confi ned to the leader peptide and cytoplasmatic tail, whereas residues of the alpha 1 domain, involved in peptide-binding, are conserved between humans, chimpanzees and rhesus macaques. Furthermore, from the 11 Mamu-DRB region confi gurations present in this panel, 28 cDRB alleles were isolated. For some exon 2 DRB sequences the corresponding transcripts could not be detected, rendering such alleles as probable pseudogenes. Evidence is presented that DRA alleles are strongly coupled to certain DRB region confi gurations, constituting 12 distinct DRA/DRB confi gurations which express maximally up to three -DRB genes. This study illustrates that there are marked differences between the HLA-and Mamu-DR regions.
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THE IMPACT OF AMINO-ACID SUBSTITUTIONS AT SPECIFIC POSITIONS OF THE HLA CLASS I MOLECULES ON ALLOREACTIVE T-CELL PRECURSOR FREQUENCIES
PSMA -SPECIFIC RESPONSES IN PATIENTS WITH PROSTATE
